Schroder Investment Management Group
ESPR icon

Schroder Investment Management Group’s Esperion Therapeutics ESPR Stock Holding History

Schroder Investment Management Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-81,200
Closed -$7.36M – 1218
2015
Q1 		$7.36M Buy
+81,200
New +$5.24M 0.01% 704

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Schroder Investment Management Group's ESPR Position: Q2 2015 in Review

Schroder Investment Management Group sold out of Esperion Therapeutics (ESPR) in Q2 2015, closing a stake of 81,200 shares — an estimated $7.36M sold.

Schroder Investment Management Group first reported a position in ESPR in Q1 2015 and held it in 1 quarter. The position peaked at $7.36M in Q1 2015. 151 funds tracked by Wall St. Rank hold ESPR as of Q2 2015.

  • Schroder Investment Management Group reported no remaining Esperion Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Schroder Investment Management Group sold 81,200 Esperion Therapeutics shares in Q2 2015, an estimated $7.36M.
  • Schroder Investment Management Group first reported a position in Esperion Therapeutics in Q1 2015 and held it in 1 quarter.
  • Schroder Investment Management Group's Esperion Therapeutics position peaked at $7.36M in Q1 2015.
  • 151 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2015.

Based on Schroder Investment Management Group's 13F filing for Q2 2015, filed 10 Aug 2015.